NVCT
Nuvectis Pharma, Inc.NASDAQHealthcare$7.56+1.19%ClosedMarket Cap: $200.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
9.06
P/S
0.00
EV/EBITDA
-6.20
DCF Value
$1.18
FCF Yield
-7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-131.8%
ROA
-83.4%
ROIC
-149.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-7.6M | $-7.3M | $-0.31 | — |
| FY 2025 | $0.00 | NaN% | $-27.6M | $-26.4M | $-1.32 | — |
| Q3 2025 | $0.00 | NaN% | $-7.8M | $-7.5M | $-0.44 | — |
| Q2 2025 | $0.00 | NaN% | $-6.6M | $-6.3M | $-0.30 | — |
| Q1 2025 | $0.00 | NaN% | $-5.6M | $-5.3M | $-0.27 | — |
| Q4 2024 | $0.00 | NaN% | $-6.4M | $-6.2M | $-0.34 | — |
| FY 2024 | $0.00 | NaN% | $-19.8M | $-19.0M | $-1.11 | — |
| Q3 2024 | $0.00 | NaN% | $-4.4M | $-4.2M | $-0.24 | — |
| Q2 2024 | $0.00 | NaN% | $-4.6M | $-4.4M | $-0.26 | — |
| Q1 2024 | $0.00 | NaN% | $-4.4M | $-4.2M | $-0.25 | — |
| Q4 2023 | $0.00 | NaN% | $-6.9M | $-6.6M | $-0.42 | — |
| FY 2023 | $0.00 | NaN% | $-22.9M | $-22.3M | $-1.43 | — |